Theophylline Antibody (201): sc-66088

Theophylline Antibody (201) is a mouse monoclonal IgG1 antibody that detects Theophylline protein of non-species reactive by enzyme-linked immunosorbent assay (ELISA). Anti-Theophylline antibody (201) is available as the non-conjugated format. Theophylline is a colorless crystalline alkaloid derived from tea leaves or synthesized in laboratories, and functions as a methylxanthine drug, closely related to caffeine in both structure and pharmacological effects. Theophylline plays a crucial role in respiratory health, acting as a bronchial dilator for conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Theophylline′s mechanism of action involves inhibition of transforming growth factor-beta (TGF-β) regulated conversion of pulmonary fibroblasts into myofibroblasts through cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) pathway, which is vital for maintaining normal lung function. Additionally, Theophylline suppresses COL1 mRNA expression, which encodes collagen, thereby influencing tissue remodeling and inflammation. Furthermore, Theophylline directly activates histone deacetylase (HDAC), an enzyme that plays a significant role in mediating inflammatory responses, leading to a decrease in interleukin-4 (IL-4) and cyclic guanosine monophosphate (cGMP) levels, highlighting its importance in therapeutic strategies for respiratory diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Theophylline Antibody (201) References:

1. Theophylline: new perspectives for an old drug.  |  Barnes, PJ. 2003. Am J Respir Crit Care Med. 167: 813-8. PMID: 12623857
2. Effects of theophylline on plasma levels of interleukin-4, cyclic nucleotides and pulmonary functions in patients with chronic obstructive pulmonary disease.  |  Zhang, N., et al. 1999. J Tongji Med Univ. 19: 15-9. PMID: 12840867
3. [Development of theophylline in treatment of asthma and chronic obstructive pulmonary disease].  |  Xu, YJ. 2004. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 26: 319-22. PMID: 15266839
4. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.  |  Broseghini, C., et al. 2005. Pulm Pharmacol Ther. 18: 103-8. PMID: 15649852
5. Theophylline in chronic obstructive pulmonary disease: new horizons.  |  Barnes, PJ. 2005. Proc Am Thorac Soc. 2: 334-9; discussion 340-1. PMID: 16267358
6. Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo-controlled trial.  |  Bhat, MA., et al. 2006. J Pediatr. 149: 180-4. PMID: 16887430
7. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year.  |  Zhou, Y., et al. 2006. Respirology. 11: 603-10. PMID: 16916334
8. Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline.  |  Lee, DW., et al. 2006. Respir Res. 7: 112. PMID: 16930490
9. Theophylline for COPD.  |  Barnes, PJ. 2006. Thorax. 61: 742-4. PMID: 16936233